Previous 10 | Next 10 |
- Expansion of Population-Scale Molecular Diagnostics Menu Positions ADCL Subsidiary for Long-Term Growth - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subs...
- Award Supports Innovation and Growth of Local Life Sciences Industry - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of an up to $1.5 million award from New York State’s Empire St...
Applied DNA Sciences, Inc. (APDN) Q1 2023 Earnings Conference Call February 09, 2023 04:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President and Chief Executive Officer Clay Shorr...
The following slide deck was published by Applied DNA Sciences, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Applied DNA Sciences, Inc. 2023 Q1 - Results - Earnings Call Presentation
Applied DNA Sciences press release ( NASDAQ: APDN ): Q1 GAAP EPS of -$0.30 misses by $0.01 . Revenue of $5.26M (+26.1% Y/Y) beats by $1.09M . Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers. Maintains Timeline to cGMP Capaci...
- Total Revenues of $5.3 Million, Up 48% Over FQ4 2022 and 26% Over FQ1 2022, 72% and 74% Reduction in Operating Loss, Respectively - - Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers - - Maintains Timeline to cGMP Capacity, Initiates Build...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes ...
- Company Advances Lipid Nanoparticle (LNP)-based Delivery System to Potentially Broaden LinearDNA Platform Commercial Utility - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer...
- Delivers 17% Revenue Growth Q/Q and 101% Y/Y - - Cash and Cash Equivalents at $15.2 Million - - Company to Hold Conference Call and Webcast Today, Wednesday, December 14, 2022, at 4:30 PM ET - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” o...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022. The Company’...
News, Short Squeeze, Breakout and More Instantly...
Applied DNA Sciences Inc. Company Name:
APDN Stock Symbol:
NASDAQ Market:
Applied DNA Sciences Inc. Website:
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCES...